<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006341</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066588</org_study_id>
    <secondary_id>UCLA-HSPC-940205413</secondary_id>
    <secondary_id>UCLA-DEN-1R01DE11255</secondary_id>
    <secondary_id>UCLA-HSPC-940205411</secondary_id>
    <secondary_id>NCI-V00-1606</secondary_id>
    <nct_id>NCT00006341</nct_id>
  </id_info>
  <brief_title>Dentures and Dental Implants in Treating Patients Undergoing Surgery for Mouth Cancer</brief_title>
  <official_title>Efficacy of Implant-Supported Maxillofacial Prostheses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: The use of dentures and dental implants may help maintain chewing and speaking&#xD;
      ability following surgery to remove tumors in the mouth.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of dentures and dental implants in&#xD;
      maintaining the ability to chew and speak in patients undergoing surgery for mouth cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether conventional or implant supported dental prostheses and current&#xD;
           surgical reconstructive procedures restore oral function and quality of life to&#xD;
           pre-cancer surgery levels in patients with early oral cancer.&#xD;
&#xD;
      OUTLINE: Patients complete a series of objective and subjective functional tests,&#xD;
      questionnaires, and baseline examinations. Within 1-5 days, patients undergo the composite&#xD;
      resection, including reconstructive surgery for the mandibulectomy group. Patients in the&#xD;
      maxillectomy group receive an immediate maxillary surgical obturator. Approximately 6 weeks&#xD;
      after ablative surgery, some patients receive radiotherapy for 5-7 weeks.&#xD;
&#xD;
      Patients receive 2-4 implants at 12-16 weeks after completion of radiotherapy or 8-16 weeks&#xD;
      after ablative surgery. Patients then receive conventional dentures at 4-22 weeks after&#xD;
      implant surgery. Implants are exposed during 27-48 weeks after placement and abutments&#xD;
      connected for fabricating dental prostheses. Approximately 8 weeks are needed to fabricate&#xD;
      the implant supported prosthesis.&#xD;
&#xD;
      Patients complete quality of life and other questionnaires prior to and at 8-21 weeks after&#xD;
      surgery, 16 weeks after conventional denture insertion, and then 16 weeks after implant&#xD;
      supported prosthesis insertion.&#xD;
&#xD;
      Patients are followed every 6 months for at least 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 62 patients (22 requiring maxillectomy and 40 requiring&#xD;
      mandibulectomy) will be accrued for this study within 42 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1997</start_date>
  <completion_date type="Actual">May 2003</completion_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Implant</intervention_name>
    <description>A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.</description>
    <arm_group_label>Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of early oral cancer lesions requiring one of the following:&#xD;
&#xD;
               -  Partial or total unilateral maxillectomy OR&#xD;
&#xD;
               -  Partial lateral mandibulectomy with or without partial glossectomy&#xD;
&#xD;
          -  Edentulous or edentulous in the maxillary arch prior to or after ablative surgery&#xD;
             (maxillectomy group)&#xD;
&#xD;
          -  Partial mandibulectomy leaving the condyles intact bilaterally (mandibulectomy group)&#xD;
&#xD;
          -  Must have sufficient bone in the selected implant sites to accommodate 2-4 implants of&#xD;
             at least 10 mm in length&#xD;
&#xD;
          -  No temporomandibular dysfunction and/or functionally restrictive opening&#xD;
&#xD;
          -  No requirement for total glossectomy, reconstructive maxillary surgery, or maxillary&#xD;
             sinus lift&#xD;
&#xD;
          -  No requirement for radiotherapy after mandibular reconstructive surgery&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  35 to 80&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No oral discomfort that would preclude study&#xD;
&#xD;
          -  No complications after ablative or reconstructive surgery that would preclude dental&#xD;
             rehabilitation with implants&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior or concurrent radiotherapy of greater than 5,500 cGY to potential implant&#xD;
             site&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal R. Garrett, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>October 4, 2000</study_first_submitted>
  <study_first_submitted_qc>May 28, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2003</study_first_posted>
  <last_update_submitted>January 29, 2016</last_update_submitted>
  <last_update_submitted_qc>January 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I lip and oral cavity cancer</keyword>
  <keyword>stage II lip and oral cavity cancer</keyword>
  <keyword>stage III lip and oral cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

